|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 23-11-10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 23-07-25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 2018-08-31 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 2022-12-31 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 2014-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 2014-06-03 |
Eric Cornut
BRD | Director/Board Member | 69 | 2016-08-25 |
Günter von Au
CHM | Chairman | 75 | 2017-09-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -1.95% | - | - | 5.73B | |
| -0.66% | +0.44% | +14.72% | +76.40% | 48.36B | |
| +2.20% | +1.41% | +61.04% | +111.43% | 35.8B | |
| +1.26% | -0.57% | -5.20% | +34.48% | 11.83B | |
| -0.46% | -3.06% | +14.15% | +80.63% | 11.48B | |
| -0.37% | -0.37% | +37.89% | +137.78% | 9.01B | |
| +1.52% | +0.39% | +48.79% | -5.82% | 6.99B | |
| -0.17% | -2.92% | +13.13% | +30.45% | 6.7B | |
| -0.59% | -1.95% | +2.23% | +178.07% | 6.42B | |
| -7.92% | -13.61% | -34.97% | -4.08% | 5.3B | |
| Average | -0.52% | -2.10% | +16.87% | +71.04% | 14.76B | |
| Weighted average by Cap. | +0.11% | -0.51% | +25.35% | +81.36% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
